PMID- 18837736
OWN - NLM
STAT- MEDLINE
DCOM- 20081210
LR  - 20081007
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 38
IP  - 9
DP  - 2008 Sep
TI  - Anti-oxidized low-density lipoprotein antibody levels are associated with the 
      development of type 2 diabetes mellitus.
PG  - 615-21
LID - 10.1111/j.1365-2362.2008.01988.x [doi]
AB  - BACKGROUND: Anti-oxidized low-density lipoprotein (LDL) antibodies are associated 
      with the oxidative capacity of plasma, but whether they protect or promote 
      diabetes is unknown. We undertook a prospective study to determine the predictive 
      capacity of anti-oxidized LDL antibodies for the onset of type 2 diabetes 
      mellitus (T2DM). MATERIALS AND METHODS: We selected 391 non-diabetic women aged 
      18-65 years. The subjects were classified as being normal (oral glucose test 
      tolerance normal, OGTT-N), or having impaired glucose tolerance (IGT), impaired 
      fasting glucose (IFG) or T2DM according to their baseline glucose levels and 
      after an OGTT. The same subjects were studied six years later. The levels of 
      anti-oxidized LDL antibodies were classified as above or below the 50th 
      percentile. RESULTS: Of the women who were OGTT-N at the start of the study and 
      who had anti-oxidized LDL antibody levels below the 50th percentile, only 65.1% 
      were still OGTT-N after 6 years versus 79.5% of those who had anti-oxidized LDL 
      antibody levels above the 50th percentile (P = 0.015). Women who had IGT or IFG 
      at the start of the study whose anti-oxidized LDL antibody levels were below the 
      50th percentile had a relative risk of 9.79 (95% confidence interval, 1.40-68.45) 
      of developing diabetes (P < 0.001). Logistic regression analysis showed that the 
      variables predicting the development of a carbohydrate metabolism disorder in the 
      women after 6 years were body mass index (P < 0.001) and the levels of 
      anti-oxidized LDL antibodies (P = 0.042). CONCLUSIONS: Levels of anti-oxidized 
      LDL antibodies are independent predictors for the development of T2DM in women.
FAU - Garrido-Sanchez, L
AU  - Garrido-Sanchez L
AD  - Endocrinology and Nutrition Service, Virgen de la Victoria Clinical Hospital, 
      Malaga, Spain.
FAU - Cardona, F
AU  - Cardona F
FAU - Garcia-Fuentes, E
AU  - Garcia-Fuentes E
FAU - Rojo-Martinez, G
AU  - Rojo-Martinez G
FAU - Gomez-Zumaquero, J M
AU  - Gomez-Zumaquero JM
FAU - Picon, M J
AU  - Picon MJ
FAU - Soriguer, F
AU  - Soriguer F
FAU - Tinahones, F J
AU  - Tinahones FJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Antibodies)
RN  - 0 (Blood Glucose)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (oxidized low density lipoprotein)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antibodies/*analysis
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus, Type 2/*immunology
MH  - Female
MH  - Follow-Up Studies
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Lipoproteins, LDL/*immunology/metabolism
MH  - Middle Aged
MH  - Risk Factors
EDAT- 2008/10/08 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/10/08 09:00
PHST- 2008/10/08 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/10/08 09:00 [entrez]
AID - ECI1988 [pii]
AID - 10.1111/j.1365-2362.2008.01988.x [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2008 Sep;38(9):615-21. doi: 10.1111/j.1365-2362.2008.01988.x.